Humira and Enbrel Biosimilars
There are 7 adalimumab biosimilar approved, but none have launched due to settlement agreements with Abbvie, the maker of Humira. The first adalimumab biosimilar expected to launch in the United States is Amjevita from Amgen. Cyltezo isn’t expected to launch until July 1, 2023, but it is the only interchangeable adalimumab biosimilar.
There are only 2 approved etanercept biosimilars: Erelzi approved August 2016 and Eticovo approved April 2019. However, neither has a launch date due to legal challenges from Amgen, the maker of Enbrel. A recent court decision in December 2021 ruled the patents on Enbrel are good until 2029.